Cortice Announces Enrollment of a Phase 1 Clinical Trial Evaluating TPI 287 in Rare Tauopathy Diseases - rPeptide

Skip to content

Products
Services
Resources
About
- Our Company
- Contact Information
Sign In

Search for:

Sign In
$0.00 0

Products
Services
Resources
About

Search for:

Antibodies

Beta-Amyloid Antibodies
Synuclein
Tau

Peptides

Amylin
Amyloid Precursor Protein Related Peptide
Beta-Amyloid

Proteins

Apolipoprotein
Chemokine
Calmodulin
Human Plasma Proteins
Surfactants
Synuclein
Tau
Tubulin

Neurodegenerative Related Compounds Coronavirus Research Tools

COVID-19/ Sars-Cov-2 Related Compounds
COVID-19/ Sars-Cov-2 Related Proteins

Kits

Beta-Amyloid
Tau

Preformed Fibrils

Beta-Amyloid Preformed Fibrils
Synuclein Preformed Fibrils
Tau Preformed Fibrils

Custom Peptides & Proteins
Lab Services
Bulk Quote
Amino Acid Codes

Citations
Blogs
International Distributors
FAQs
Ordering Overview
Terms of Use

Our Company
Contact Information

News

July 6, 2014
Market Watch:Cortice Announces Enrollment of a Phase 1 Clinical Trial Evaluating TPI 287 in Rare Tauopathy Diseases Cortice Announces Enrollment of a Phase 1 Clinical Trial Evaluating TPI 287 in Rare Tauopathy Diseases

View all news

Products
Antibodies
Peptides
Proteins
Neurodegenerative Related Compounds
Coronavirus Research Tools
Kits
Preformed Fibrils

Services
Custom Peptides & Proteins
Lab Services
Bulk Quote
Amino Acid Codes

Resources
Citations
Blogs
International Distributors
FAQs
Ordering Overview
Terms of Use

About
Our Company
Contact Information

rPeptide

ph: 866.753.0747 fax: 678.753.0746 e: sales@rpeptide.com

Follow Us

Newsletter Signup

© 2026

rPeptide Sitemap | Privacy | Terms & Conditions

rPeptide products are for research purposes only. Not for human consumption.